New Products: Device for temporary reduction of the appearance of cellulite
Noninvasive product is the first FDA-class II device cleared for temporary reduction of the appearance of cellulite.
Hello baby; bye-bye cellulite?
Helping women achieve their 'before baby body,' is the goal of VelaShape from Syneron Medical Ltd. (Yokneam, Israel). Could that be enough for some postpregnancy patients, even if VelaShape reduces the appearance of cellulite only temporarily?
The noninvasive product is the first FDA-class II device cleared for the temporary reduction of the appearance of cellulite-and also the first FDA-cleared device for the temporary reduction of thigh circumference, says Syneron.
A VelaShape treatment uses its elos technology (Electro-Optical Synergy), which combines infrared light energy and bipolar radiofrequency energy to send heat deeply into the tissue, with rollers to smooth the tissue. To download the study or see before and after photos, visit http://www.syneron.com/BAB.
Chemoattractants in fetal membranes enhance leukocyte migration near term pregnancy
November 22nd 2024A recent study highlights the release of chemoattractants from human fetal membranes at term, driving leukocyte activation and migration, with implications for labor and postpartum recovery.
Read More
Reproductive genetic carrier screening: A tool for reproductive decision-making
November 22nd 2024A new study highlights the efficacy of couple-based reproductive genetic carrier screening in improving reproductive decisions and outcomes, emphasizing its growing availability and acceptance among diverse populations.
Read More
Early preterm birth risk linked to low PlGF levels during pregnancy screening
November 20th 2024New research highlights that low levels of placental growth factor during mid-pregnancy screening can effectively predict early preterm birth, offering a potential tool to enhance maternal and infant health outcomes.
Read More
